Rare Disease pathways at WikiPathways
This page highlights WikiPathways content related to rare genetic human diseases, and is designed as a central organizing point for exploring, curating and expanding the collection of rare disease pathways. A rare or orphan disease is a disease which affects relatively few people. The exact definition varies between 1:1000 and 1:200.000. E.g. it can be 1:1500 (USA) , 1:2000 (EU) or 1:2500 (Japan). Rare diseases are mostly caused by genetic variation making them chronic and hard to cure. The severity depends on the affected gene and its physiological implications.
Community Pathways
This community helps to curate 83 pathways:- 15q11.2 copy number variation syndrome - WP4940 (Homo sapiens)
- 15q13.3 copy number variation syndrome - WP4942 (Homo sapiens)
- 16p11.2 distal deletion syndrome - WP4950 (Homo sapiens)
- 16p11.2 proximal deletion syndrome - WP4949 (Homo sapiens)
- 1q21.1 copy number variation syndrome - WP4905 (Homo sapiens)
- 22q11.2 copy number variation syndrome - WP4657 (Homo sapiens)
- 3q29 copy number variation syndrome - WP4906 (Homo sapiens)
- 7q11.23 copy number variation syndrome - WP4932 (Homo sapiens)
- Acquired partial lipodystrophy / Barraquer-Simons syndrome - WP5104 (Homo sapiens)
- Acute viral myocarditis - WP4298 (Homo sapiens)
- Alternative pathway of fetal androgen synthesis - WP4524 (Homo sapiens)
- Alzheimer's disease - WP5124 (Homo sapiens)
- Alzheimer's disease and miRNA effects - WP2059 (Homo sapiens)
- Amyotrophic lateral sclerosis (ALS) - WP2447 (Homo sapiens)
- Biosynthesis and regeneration of tetrahydrobiopterin and catabolism of phenylalanine - WP4156 (Homo sapiens)
- Biotin metabolism, including IMDs - WP5031 (Homo sapiens)
- Cerebral organic acidurias, including diseases - WP4519 (Homo sapiens)
- Cholesterol biosynthesis with skeletal dysplasias - WP4804 (Homo sapiens)
- Ciliopathies - WP4803 (Homo sapiens)
- Classical pathway of steroidogenesis with glucocorticoid and mineralocorticoid metabolism - WP4523 (Homo sapiens)
- Congenital generalized lipodystrophy - WP5101 (Homo sapiens)
- Cysteine and methionine catabolism - WP4504 (Homo sapiens)
- Degradation pathway of sphingolipids, including diseases - WP4153 (Homo sapiens)
- Development of ureteric collection system - WP5053 (Homo sapiens)
- Disorders of folate metabolism and transport - WP4259 (Homo sapiens)
- ERK pathway in Huntington's disease - WP3853 (Homo sapiens)
- Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome - WP4320 (Homo sapiens)
- Envelope proteins and their potential roles in EDMD physiopathology - WP4535 (Homo sapiens)
- Ethylmalonic encephalopathy - WP5030 (Homo sapiens)
- Familial hyperlipidemia type 1 - WP5108 (Homo sapiens)
- Familial hyperlipidemia type 2 - WP5109 (Homo sapiens)
- Familial hyperlipidemia type 3 - WP5110 (Homo sapiens)
- Familial hyperlipidemia type 4 - WP5111 (Homo sapiens)
- Familial hyperlipidemia type 5 - WP5112 (Homo sapiens)
- Familial partial lipodystrophy - WP5102 (Homo sapiens)
- Fragile X syndrome - WP4549 (Homo sapiens)
- GABA metabolism (aka GHB) - WP4157 (Homo sapiens)
- GDNF/RET signaling axis - WP4830 (Homo sapiens)
- Gamma-glutamyl cycle for the biosynthesis and degradation of glutathione, including diseases - WP4518 (Homo sapiens)
- Genes controlling nephrogenesis - WP4823 (Homo sapiens)
- Glycosylation and related congenital defects - WP4521 (Homo sapiens)
- Hippo signaling regulation pathways - WP4540 (Homo sapiens)
- Hippo-Merlin signaling dysregulation - WP4541 (Homo sapiens)
- Inclusion body myositis - WP5120 (Homo sapiens)
- Influence of laminopathies on Wnt signaling - WP4844 (Homo sapiens)
- Joubert syndrome - WP4656 (Homo sapiens)
- Kallmann syndrome - WP5074 (Homo sapiens)
- Kisspeptin/kisspeptin receptor system in the ovary - WP4871 (Homo sapiens)
- Krebs cycle disorders - WP4236 (Homo sapiens)
- Lamin A-processing pathway - WP4299 (Homo sapiens)
- MECP2 and associated Rett syndrome - WP3584 (Homo sapiens)
- MTHFR deficiency - WP4288 (Homo sapiens)
- Male infertility - WP4673 (Homo sapiens)
- Mammalian disorder of sexual development - WP4842 (Homo sapiens)
- Meta pathway lipodystrophy, dyslipidemia and hyperlipidemia - WP5105 (Homo sapiens)
- Metabolic pathway of LDL, HDL and TG, including diseases - WP4522 (Homo sapiens)
- Methionine metabolism leading to sulfur amino acids and related disorders - WP4292 (Homo sapiens)
- Molybdenum cofactor (Moco) biosynthesis - WP4507 (Homo sapiens)
- Nephrogenesis - WP5052 (Homo sapiens)
- Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway - WP4577 (Homo sapiens)
- Neurotransmitter disorders - WP4220 (Homo sapiens)
- Nitric oxide metabolism in cystic fibrosis - WP4947 (Homo sapiens)
- Overlap between signal transduction pathways contributing to LMNA laminopathies - WP4879 (Homo sapiens)
- Oxysterols derived from cholesterol - WP4545 (Homo sapiens)
- Parkinson's disease pathway - WP2371 (Homo sapiens)
- Peroxiredoxin 2 induced ovarian failure - WP4835 (Mus musculus)
- Phosphoinositides metabolism - WP4971 (Homo sapiens)
- Prader-Willi and Angelman syndrome - WP3998 (Homo sapiens)
- Prion disease pathway - WP3995 (Homo sapiens)
- Progeria-associated lipodystrophy - WP5103 (Homo sapiens)
- Purine metabolism - WP4792 (Homo sapiens)
- Purine metabolism and related disorders - WP4224 (Homo sapiens)
- Pyrimidine metabolism and related diseases - WP4225 (Homo sapiens)
- Rett syndrome causing genes - WP4312 (Homo sapiens)
- Riboflavin and CoQ disorders - WP5037 (Homo sapiens)
- Serine metabolism - WP4688 (Homo sapiens)
- Somatic sex determination - WP4814 (Homo sapiens)
- Thiamine metabolic pathways - WP4297 (Homo sapiens)
- Thyroid hormones production and peripheral downstream signaling effects - WP4746 (Homo sapiens)
- Tyrosine metabolism and related disorders - WP4506 (Homo sapiens)
- Urea cycle and associated pathways - WP4595 (Homo sapiens)
- Vitamin B12 disorders - WP4271 (Homo sapiens)
- Vitamin B6-dependent and responsive disorders - WP4228 (Homo sapiens)
How to Contribute
If you know of a pathway that should be added, please contact the administrator (friederike.ehrhart[AT]gmail.com).
Support
This project has received funding from the European Union’s Horizon 2020 research and innovation programme (to the European Joint Programme on Rare Diseases and to ELIXIR) and the Netherlands Rett Expertise Centre.
Authors of Community Pathways
Friederike Ehrhart , Egon Willighagen , Kristina Hanspers , Marvin Martens , Denise Slenter , Victor Avramov , Maintenance bot , Lauren J. Dupuis , Magda M. Latorre , Ulas Babayigit , Eric Weitz , Olivier Traets , Finterly Hu , Eline Sanders , Irene Hemel , Nathan Salomonis , Thomas Kelder , Alex Pico , Jonathan Mlius , Lovnish Thakur , Susan Coort , Anders Riutta , Tyler Peryea , Martina Summer-Kutmon , Daniela Digles , Josien Landman , Britt Pieters , Eveline Schoenmaker , Ritchie Lee , Ingebude , Daniel Domingo-Fdez , Andra Waagmeester , Ado , Jesse Vercoulen , AAR&Co , Andika Tan , Nirupama Benis , Lora Simons , Laurent Winckers , Megi Kass , Elisson nl , Vanessa Sousa , Lars Willighagen , Yasmin Omar , Lobke Meels , Iulia Ioncu , Zoe Barois , Anna De Brouwer , Marijn Kerkhofs , Margit Janssen , Richard Delava , Ryan Miller , Anouk Wolters , Hermann Ritter , G. Keulen , Ann Friesacher , Conroy lipids , Bas Lahaije , Elisa Santarsiero , Kelly Janssen , Lot Van De Wouw , Roel Hacking , Max Van Son , Amy Kutmon , Je G , Youssef Walid , Rik Lahaije , Agustin Gonzalez-Vicente , Mzolisi Mtshaulana , and Lisa Martina Held .